Drug intelligence / Profile preview

NOROMBY

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Administration: Subcutaneous, Intravenous

Overview

NOROMBY is a biosimilar of the reference biologic Lovenox (enoxaparin sodium), developed by Juno Pharma Canada (formed by the merger of Juno Pharmaceuticals and Omega Laboratories). As a low molecular weight heparin (LMWH), it functions as an anticoagulant by binding to and enhancing the activity of antithrombin III, which subsequently inhibits clotting factors Xa and IIa (thrombin). NOROMBY is indicated for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the management of acute coronary syndromes. It is available in standard (NOROMBY) and high-potency (NOROMBY HP) formulations for subcutaneous or intravenous administration.

Brand names: NOROMBYNOROMBY HP
Other names: enoxaparin sodium

Targets

ATIII (Antithrombin III)F10 (Factor Xa)F2 (Thrombin)

Beyond the preview

Go deeper on NOROMBY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOROMBY.

Explore the full profile